JP6509844B2 - 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 - Google Patents

皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 Download PDF

Info

Publication number
JP6509844B2
JP6509844B2 JP2016526337A JP2016526337A JP6509844B2 JP 6509844 B2 JP6509844 B2 JP 6509844B2 JP 2016526337 A JP2016526337 A JP 2016526337A JP 2016526337 A JP2016526337 A JP 2016526337A JP 6509844 B2 JP6509844 B2 JP 6509844B2
Authority
JP
Japan
Prior art keywords
composition
salt
skin
nicotinamide riboside
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016526337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538271A5 (enExample
JP2016538271A (ja
Inventor
デレン−ルイス,アン
ローンマス,トロイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromadex Inc
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of JP2016538271A publication Critical patent/JP2016538271A/ja
Publication of JP2016538271A5 publication Critical patent/JP2016538271A5/ja
Application granted granted Critical
Publication of JP6509844B2 publication Critical patent/JP6509844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/18Antioxidants, e.g. antiradicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cosmetics (AREA)
JP2016526337A 2013-10-30 2014-10-30 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 Active JP6509844B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361897713P 2013-10-30 2013-10-30
US61/897,713 2013-10-30
PCT/US2014/063260 WO2015066382A1 (en) 2013-10-30 2014-10-30 Nicotinamide riboside compositions for topical use in treating skin conditions

Publications (3)

Publication Number Publication Date
JP2016538271A JP2016538271A (ja) 2016-12-08
JP2016538271A5 JP2016538271A5 (enExample) 2017-12-21
JP6509844B2 true JP6509844B2 (ja) 2019-05-08

Family

ID=53005146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526337A Active JP6509844B2 (ja) 2013-10-30 2014-10-30 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物

Country Status (12)

Country Link
US (2) US10688118B2 (enExample)
EP (1) EP3063163B1 (enExample)
JP (1) JP6509844B2 (enExample)
KR (3) KR20160067195A (enExample)
CN (2) CN105873937A (enExample)
AU (1) AU2014342185B2 (enExample)
CA (1) CA2928656C (enExample)
ES (1) ES2925879T3 (enExample)
MX (2) MX394291B (enExample)
NZ (1) NZ719328A (enExample)
WO (1) WO2015066382A1 (enExample)
ZA (1) ZA201603314B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536535A (zh) * 2014-06-02 2017-03-22 葛兰素史密斯克莱知识产权(第2 号)有限公司 结晶的β‑D‑烟酰胺核苷的制备和用途
WO2015186114A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
WO2016014927A2 (en) 2014-07-24 2016-01-28 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
KR102629310B1 (ko) 2015-03-09 2024-01-24 더블유.알. 그레이스 앤드 캄파니-콘. 니코틴아미드 리보사이드의 결정 형태
US10280190B2 (en) * 2015-03-16 2019-05-07 Chromadex, Inc. Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions
JP6611099B2 (ja) * 2015-05-01 2019-11-27 ザ プロクター アンド ギャンブル カンパニー 皮膚の健康を改善する方法及びそのための組成物
JP2018515486A (ja) 2015-05-01 2018-06-14 ザ プロクター アンド ギャンブル カンパニー ニコチンアミドリボシドを用いた皮膚外観の改善方法及びそのための組成物
EP3288530A1 (en) 2015-05-01 2018-03-07 The Procter and Gamble Company Method of improving the appearance of skin and compositions therefor using nicotinamide riboside
KR20180021784A (ko) * 2015-06-10 2018-03-05 엘리시움 헬스, 인크. 피부병의 치료를 위한 니코틴아미드 리보시드 및 프테로스틸벤 조성물 및 방법
US20180177703A1 (en) * 2015-06-25 2018-06-28 N.V. Perricone Llc Niacinamide Mononucleotide Formulations For Skin Aging
US20160374918A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Encapsulated skin care agent
WO2017004101A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Skin care compositions comprising particles with nicotinamide riboside and methods of using the same
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
CN108430449B (zh) 2016-01-11 2023-01-24 宝洁公司 处理皮肤状况的方法以及用于其的组合物
AU2017232930B2 (en) 2016-03-16 2021-03-25 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
MX393076B (es) * 2016-04-20 2025-03-24 Chromadex Inc Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+
BR112019003579A2 (pt) * 2016-08-22 2019-05-21 Elysium Health, Inc. Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
CN110662542B (zh) 2016-11-11 2025-04-08 英国贝尔法斯特女王大学 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、其磷酸化的类似物、其腺苷二核苷酸共轭物、以及其新颖结晶形式的有效且可规模化的合成
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
US11633421B2 (en) 2016-11-29 2023-04-25 University Of Iowa Research Foundation Use of NAD precursors for improving maternal health and/or offspring health
CN110121330B (zh) 2016-12-21 2022-04-29 联合利华知识产权控股有限公司 具有包含4-取代的间苯二酚和氨基酸的谷胱甘肽前体的个人护理组合物
JP7084924B2 (ja) 2016-12-21 2022-06-15 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ 難溶性化合物を含むパーソナルケア組成物
EP3558255B1 (en) 2016-12-21 2021-10-13 Unilever IP Holdings B.V. Topical skin lightening additive and composition with amino acids and nicotinamide compounds
EA201991185A1 (ru) 2016-12-21 2020-01-13 Юнилевер Н.В. Композиции для личной гигиены, содержащие цистин
RU2651047C1 (ru) * 2017-05-04 2018-04-18 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственная композиция цитопротекторного действия и способ ее получения
WO2018213715A1 (en) * 2017-05-18 2018-11-22 Elysium Health, Inc. Methods and compositions for improving sleep
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
EP3641725A1 (en) 2017-06-23 2020-04-29 The Procter and Gamble Company Composition and method for improving the appearance of skin
CA3108015A1 (en) 2017-07-28 2019-01-31 Centers For Age Control, Inc. Compositions and methods for preventing and reversing aspects of aging
CN111093397A (zh) * 2017-09-14 2020-05-01 田中惠 一种抗衰老剂以及抗衰老方法
GB201716391D0 (en) * 2017-10-06 2017-11-22 Xobaderm Ltd Kit for delivery of an active compound into a biological barrier
CN112020363A (zh) 2017-12-22 2020-12-01 益力舒健康公司 烟酰胺核苷氯化物的结晶形式
CN112437657A (zh) 2018-07-03 2021-03-02 宝洁公司 处理皮肤状况的方法
WO2019210607A1 (zh) * 2018-08-17 2019-11-07 邦泰生物工程(深圳)有限公司 一种稳定型烟酰胺核糖组合物及其制备方法
KR102060374B1 (ko) * 2018-12-14 2019-12-30 주식회사 휴메딕스 지방알코올 컨쥬게이션된 니코틴아미드 리보사이드 유도체
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
MX2022000774A (es) * 2019-07-19 2022-05-03 Biosynth Ag Metodo para elaborar sales de ribofuranosido de nicotinamida, sales de ribofuranosido de nicotinamida como tal, y usos de las mismas.
CN110638827A (zh) * 2019-10-17 2020-01-03 泓博元生命科技(深圳)有限公司 Nadh及其盐在制备皮肤色素抑制剂中的应用
KR102315139B1 (ko) 2019-12-17 2021-10-20 주식회사 휴메딕스 지방아민 컨쥬게이션된 니코틴아미드 리보사이드 유도체
CN111166760A (zh) * 2019-12-17 2020-05-19 浙江安赛新材料科技有限公司 β-烟酰胺单核苷酸或其前体的组合物及制备方法、应用
CN111184732B (zh) * 2020-03-04 2023-09-08 武汉华纳联合药业有限公司 一种复合组合物制剂及其制备方法和皮肤炎症中的应用
CN111454311B (zh) * 2020-04-03 2021-10-19 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
EP4153323A1 (fr) * 2020-05-20 2023-03-29 Nuvamid SA Compositions cosmetiques anti-age comprenant du nmn
FR3110410A1 (fr) * 2020-05-20 2021-11-26 Nuvamid Sa Compositions cosmétiques anti-âge comprenant de la NMN
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
JP7590462B2 (ja) 2020-06-01 2024-11-26 ザ プロクター アンド ギャンブル カンパニー ビタミンb3化合物の皮膚への浸透を改善する方法
CN111632049A (zh) * 2020-06-09 2020-09-08 西北农林科技大学 一种通过综合矫正细胞活性氧簇代谢紊乱以缓解睾丸衰老损伤的复合配方
WO2022047182A1 (en) * 2020-08-28 2022-03-03 University Of Washington High dose nicotinamide adenine dinucleotide (nad) precursor regimens for reduction of inflammation in human patients with preexisting inflammation
EP4029496A1 (en) * 2021-01-18 2022-07-20 Universitat de València Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
US20240059727A1 (en) * 2021-01-19 2024-02-22 Biosynth Ag Method of making nicotinamide ribofuranoside salts by salt metathesis, the crystalline form of its tosylate salt and the co-crystallized form of its chloride:iodide salt
EP4333807A1 (en) * 2021-05-04 2024-03-13 Sovida Solutions Ltd. Nicotinamide adenine dinucleotide (nad) compositions, methods of manufacturing thereof, and methods of use thereof
CN114129509B (zh) * 2021-12-03 2023-12-01 药酚享科技(北京)有限公司 一种保湿性nmn亲水凝胶剂及其制备方法
CN116621898A (zh) * 2022-04-13 2023-08-22 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其结晶形态、制备方法与用途
KR102784901B1 (ko) * 2022-06-23 2025-03-21 제너럴바이오(주) Nr, nmn 및 nad를 함유한 피부 주름 개선용 화장료 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007314A (es) * 2001-02-22 2003-12-04 Unilever Nv Composicion para la piel para reducir aceites y grasa de la piel.
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2555675A1 (en) 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
CN1964627B (zh) 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
EP1877054A2 (en) 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CN101257897A (zh) * 2005-07-07 2008-09-03 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
DK1957086T3 (en) * 2005-11-18 2018-06-06 Cornell Res Foundation Inc NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE
CN101631593B (zh) * 2007-03-12 2014-08-13 帝斯曼知识产权资产管理有限公司 化妆品组合物
US20090069444A1 (en) 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
MX2012007873A (es) * 2010-01-06 2012-07-25 Yakult Honsha Kk Promotor de reparacion del daño de acido desoxirribonucleico para aplicacion oral e inhibidor de la actividad de elastasa para apalicacion oral.

Also Published As

Publication number Publication date
US20160250241A1 (en) 2016-09-01
EP3063163A1 (en) 2016-09-07
US11033568B2 (en) 2021-06-15
AU2014342185B2 (en) 2019-01-03
WO2015066382A1 (en) 2015-05-07
CA2928656A1 (en) 2015-05-07
CN109985056A (zh) 2019-07-09
KR20210107895A (ko) 2021-09-01
MX385305B (es) 2025-03-18
EP3063163A4 (en) 2017-05-10
CN105873937A (zh) 2016-08-17
MX394291B (es) 2025-03-24
KR20160067195A (ko) 2016-06-13
ES2925879T3 (es) 2022-10-20
KR20220098049A (ko) 2022-07-08
EP3063163B1 (en) 2022-08-10
CA2928656C (en) 2020-07-28
MX2021009652A (es) 2022-07-26
ZA201603314B (en) 2017-09-27
US10688118B2 (en) 2020-06-23
JP2016538271A (ja) 2016-12-08
US20200289536A1 (en) 2020-09-17
MX2016005574A (es) 2016-12-09
NZ719328A (en) 2022-04-29

Similar Documents

Publication Publication Date Title
US11033568B2 (en) Nicotinamide riboside compositions for topical use in treating skin conditions
AU2014342185A1 (en) Nicotinamide riboside compositions for topical use in treating skin conditions
TWI257303B (en) A method for enhancing protective cellular responses to genotoxic stress in skin
Haque et al. Topical therapies for skin cancer and actinic keratosis
BR112014025469B1 (pt) Usos de lisado filtrado da bactéria probiótica lactobacillus rhamnosus gg atcc 53103 no reparo ou regeneração da barreira cutânea e no tratamento cosmético para aumentar a função de barreira cutânea
TW201210601A (en) Compounds and methods for skin repair
EA024483B1 (ru) Местная композиция для лечения гиперкератотической кожи
US8816065B2 (en) Pharmaceutical or cosmetic composition containing nicotinic acid adenine dinucleotide phosphate or derivative thereof
KR20100135703A (ko) 주름 억제용 조성물과 피부 외용 조성물
JP2017528505A (ja) 発毛増進、皮膚再生促進及び創傷治癒のための組成物及び方法
ES2827253T3 (es) Preparación cutánea externa antienvejecimiento
WO2016196950A1 (en) Olivamine-induced improvement in endothelial cells viability and function
EP0535237A1 (en) Composition for relieving skin irritation and external preparation for percutaneous adminstration containing the same
KR101446706B1 (ko) Fgf를 포함하는 피부 재생용 조성물
JP5455248B2 (ja) 保湿作用を有する皮膚外用剤
RU2720993C2 (ru) Пирролидон-карбоновая кислота (рса) для офтальмологического применения
HK40011054A (en) Nicotinamide nucleoside composition for topical use in the treatment of dermatosis
US20230372437A1 (en) Compositions and methods for the treatment of hair loss and other conditions
US20230390291A1 (en) Treatment of skin disorders with compositions comprising an egfr inhibitor
JP7396585B2 (ja) Tslp遺伝子発現抑制用、il-33遺伝子発現抑制用、又はフィラグリン産生促進用組成物
US20250114362A1 (en) Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions
RU2793250C2 (ru) Композиция и способы лечения патологических состояний кожи; использование света и гидрохлорида глюкозамина
JP2007153863A (ja) 毛髪改善外用剤
US20210346380A1 (en) Treatment of skin disorders with compositions comprising an egfr inhibitor
KR20120032009A (ko) 피부 수분 투과 기능 이상의 예방제 또는 치료제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190403

R150 Certificate of patent or registration of utility model

Ref document number: 6509844

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250